EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach

Dame Idossa, Maeve A Hennessy, Alexis LeVee, Rita Nanda, Heather McArthur, Roberto A Leon-Ferre iD

American Society of Clinical Oncology Educational Book · 2026

DOI: 10.1200/edbk-26-520666 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026. Verfasst von Dame Idossa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Oncology, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Precision Medicine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 96 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by lack of estrogen receptor expression, progesterone receptor expression, and human epidermal growth factor 2 overexpression/amplification. Given its generally aggressive biology, current guidelines recommend systemic therapy for most patients, with anthracycline- and taxane-based regimens being historically preferred. However, the clinical outcomes of patients with stage I TNBC and the benefit (or lack thereof) of (neo)adjuvant chemotherapy have not been prospectively evaluated as this population has largely been excluded from prospective randomized clinical trials. As such, management decisions for stage I TNBC are typically extrapolated from trials enrolling patients with stage II or III TNBC or based on retrospective analyses. Currently, the primary factor influencing systemic therapy decisions is the anatomic stage, without other biomarkers clinically used to guide systemic therapy. This review summarizes the existing evidence supporting current and emerging systemic therapy strategies for stage I TNBC, with a special focus on treatment de-escalation and promising biomarkers that can advance personalized treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsPrecision MedicineHumansFemaleNeoplasm StagingBiomarkers, TumorTreatment Outcome

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Division of Oncology, Department of Oncology, Mayo Clinic, Rochester, MN.
  • Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.
  • University of California, Los Angeles, Los Angeles, CA.
  • Department of Medical Oncology, University of Texas Southwestern Medical Center, Dallas, TX.

ORCID-Profile: Roberto A Leon-Ferre

Zitieren

APA

Idossa, D., Hennessy, M. A., LeVee, A., Nanda, R., McArthur, H., & Leon-Ferre, R. A. (2026). Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk-26-520666

Vancouver

Idossa D, Hennessy MA, LeVee A, Nanda R, McArthur H, Leon-Ferre RA. Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach. American Society of Clinical Oncology Educational Book. 2026. doi:10.1200/edbk-26-520666

BibTeX
@article{Idossa2026,
  author = {Idossa, Dame and Hennessy, Maeve A and LeVee, Alexis and Nanda, Rita and McArthur, Heather and Leon-Ferre, Roberto A},
  title = {Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2026},
  doi = {10.1200/edbk-26-520666}
}
Kostenlos starten →